Biblio

Author Title [ Type(Desc)] Year
Filters: Author is Garcia-Manero, Guillermo  [Clear All Filters]
Journal Article
Jabbour, E., Sasaki, K., Ravandi, F., Huang, X., Short, N.J., Khouri, M., Kebriaei, P., Burger, J., Khoury, J., Jorgensen, J., et al. (2018). Chemoimmunotherapy with inotuzumab ozogamicin combined with mini-hyper-CVD, with or without blinatumomab, is highly effective in patients with Philadelphia chromosome-negative acute lymphoblastic leukemia in first salvage.Cancer.
Takahashi, K., Kantarjian, H., Garcia-Manero, G., Borthakur, G., Kadia, T., DiNardo, C., Jabbour, E., Pierce, S., Estrov, Z., Konopleva, M., et al. (2015). Clofarabine Plus Low-Dose Cytarabine Is as Effective as and Less Toxic Than Intensive Chemotherapy in Elderly AML Patients.Clin Lymphoma Myeloma Leuk.
Jabbour, E., Short, N.J., Jorgensen, J.L., Yilmaz, M., Ravandi, F., Wang, S.A., Thomas, D.A., Khoury, J., Champlin, R.E., Khouri, I., et al. (2016). Differential impact of minimal residual disease negativity according to the salvage status in patients with relapsed/refractory B-cell acute lymphoblastic leukemia.Cancer.
Daver, N., Thomas, D., Ravandi, F., Cortes, J., Garris, R., Jabbour, E., Garcia-Manero, G., Borthakur, G., Kadia, T., Rytting, M., et al. (2015). Final report of a phase II study of imatinib mesylate with hyper-CVAD for the frontline treatment of adult patients with Philadelphia chromosome positive (Ph+) acute lymphoblastic leukemia.Haematologica.
Lepore, I., Dell'aversana, C., Pilyugin, M., Conte, M., Nebbioso, A., De Bellis, F., Tambaro, F.P., Izzo, T., Garcia-Manero, G., Ferrara, F., et al. (2013). HDAC Inhibitors Repress BARD1 Isoform Expression in Acute Myeloid Leukemia Cells via Activation of miR-19a and/or b.Plos One8, e83018.
Ravandi, F., Assi, R., Daver, N., Benton, C.B., Kadia, T., Thompson, P.A., Borthakur, G., Alvarado, Y., Jabbour, E.J., Konopleva, M., et al. (2019). Idarubicin, cytarabine, and nivolumab in patients with newly diagnosed acute myeloid leukaemia or high-risk myelodysplastic syndrome: a single-arm, phase 2 study.Lancet Haematol.
Ravandi, F., Jorgensen, J.L., O'Brien, S.M., Jabbour, E., Thomas, D.A., Borthakur, G., Garris, R., Huang, X., Garcia-Manero, G., Burger, J.A., et al. (2015). Minimal residual disease assessed by multi-parameter flow cytometry is highly prognostic in adult patients with acute lymphoblastic leukaemia.Br J Haematol.
Ghanem, H., Garcia-Manero, G., Faderl, S., Ravandi, F., Cortes, J., Katragadda, L., O'Brien, S., Daver, N., Pierce, S., Kadia, T., et al. (2014). Outcomes of patients with myelodysplatic syndrome and chronic myelomonocytic leukemia post clofarabine failure.Ther Adv Hematol5, 29-34.
Dalle, I.Abou, Kantarjian, H.M., Short, N.J., Konopleva, M., Jain, N., Garcia-Manero, G., Garris, R., Qiao, W., Cortes, J.E., O'Brien, S., et al. (2019). Philadelphia chromosome-positive acute lymphoblastic leukemia at first relapse in the era of tyrosine kinase inhibitors.Am J Hematol.
Zuo, Z., Maiti, S., Hu, S., Loghavi, S., Calin, G.A., Garcia-Manero, G., Kantarjian, H.M., L Medeiros, J., Cooper, L.Jn, and Bueso-Ramos, C.E. (2014). Plasma circulating-microRNA profiles are useful for assessing prognosis in patients with cytogenetically normal myelodysplastic syndromes.Mod Pathol.
Hsu, J.I., Dayaram, T., Tovy, A., De Braekeleer, E., Jeong, M., Wang, F., Zhang, J., Heffernan, T.P., Gera, S., Kovacs, J.J., et al. (2018). PPM1D Mutations Drive Clonal Hematopoiesis in Response to Cytotoxic Chemotherapy.Cell Stem Cell23, 700-713.e6.
Short, N.J., Kantarjian, H.M., Sasaki, K., Cortes, J.E., Ravandi, F., Thomas, D.A., Garcia-Manero, G., Khouri, I., Kebriaei, P., Champlin, R.E., et al. (2016). Prognostic significance of day 14 bone marrow evaluation in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia.Cancer.
Koreth, J., Pidala, J., Perez, W.S., H Deeg, J., Garcia-Manero, G., Malcovati, L., Cazzola, M., Park, S., Itzykson, R., Ades, L., et al. (2013). Role of Reduced-Intensity Conditioning Allogeneic Hematopoietic Stem-Cell Transplantation in Older Patients With De Novo Myelodysplastic Syndromes: An International Collaborative Decision Analysis.J Clin Oncol.
Sasaki, K., Kantarjian, H.M., Kadia, T., Patel, K., Loghavi, S., Garcia-Manero, G., Jabbour, E.J., DiNardo, C., Pemmaraju, N., Daver, N., et al. (2019). Sorafenib plus intensive chemotherapy improves survival in patients with newly diagnosed, FLT3-internal tandem duplication mutation-positive acute myeloid leukemia.Cancer.